Bayer has announced new subgroup analyses from the Phase III FINEARTS-HF trial, which evaluated the efficacy of finerenone (Kerendia™) in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40% or higher. These findings will be presented at the 2024 Heart Failure Society of America (HFSA) Annual Meeting.
Key data to be presented include:
Combination of Finerenone with SGLT2 Inhibitors in HF with LVEF ≥ 40%
The study explored the effects of combining finerenone, a non-steroidal mineralocorticoid receptor (MR) antagonist, with SGLT2 inhibitors, which have both been shown to reduce cardiovascular event risk in HF patients with LVEF ≥ 40%.
- Presentation: September 28, 2024, 4:00 pm (ET) / 10:00 pm (CEST).
Time to Clinical Benefit of Finerenone
Researchers assessed how long it took for finerenone to achieve statistically significant benefits in patients with HF and LVEF ≥ 40% for the primary endpoint.
- ePoster: September 27-29, 2024.
Long-Term Benefits of Finerenone in HF with LVEF ≥ 40%
This analysis evaluated the long-term impact of finerenone on patients, using data from the FINEARTS-HF trial.
- ePoster: September 27-29, 2024.
Impact on Quality of Life Using KCCQ-TSS
The study also focused on the Kansas City Cardiomyopathy Questionnaire (KCCQ), a tool to assess symptoms and quality of life in HF patients. This analysis examined the effect of finerenone on KCCQ scores in patients with mildly reduced or preserved ejection fraction.
- Presentation: September 28, 2024, 4:53 pm (ET) / 10:53 pm (CEST), C101.
Effect of Recent HF Events on Finerenone’s Efficacy
This late-breaking analysis studied how finerenone performed in patients who had a recent heart failure event, as these patients are at high risk of hospitalization and death.
- Presentation: September 29, 2024, 9:35 am (ET) / 3:35 pm (CEST), Georgia Ballroom 2.
Finerenone’s Efficacy Across the Ejection Fraction Spectrum
Researchers also analyzed how the treatment effects of finerenone varied across the ejection fraction spectrum, demonstrating a reduction in cardiovascular deaths and worsening HF events.
- Presentation: September 29, 2024, 9:43 am (ET) / 3:43 pm (CEST), Georgia Ballroom 2.
Efficacy of Finerenone in Relation to Patient Age
Lastly, an analysis explored how the efficacy and safety of finerenone varied by age, providing insights into the treatment’s performance in different age groups.
